| Estimation of the warfarin dose with clinical and pharmacogenetic data International Warfarin Pharmacogenetics Consortium New England Journal of Medicine 360 (8), 753-764, 2009 | 1848 | 2009 |
| Clinical significance of the cytochrome P450 2C19 genetic polymorphism Z Desta, X Zhao, JG Shin, DA Flockhart Clinical pharmacokinetics 41, 913-958, 2002 | 1174 | 2002 |
| Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274) SJ Lee, BC Jang, SW Lee, YI Yang, SI Suh, YM Park, S Oh, JG Shin, ... FEBS letters 580 (3), 755-762, 2006 | 572 | 2006 |
| Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups NA Limdi, M Wadelius, L Cavallari, N Eriksson, DC Crawford, MTM Lee, ... Blood, The Journal of the American Society of Hematology 115 (18), 3827-3834, 2010 | 404 | 2010 |
| Genetic variants of the organic cation transporter 2 influence the disposition of metformin IS Song, HJ Shin, EJ Shim, IS Jung, WY Kim, JH Shon, JG Shin Clinical Pharmacology & Therapeutics 84 (5), 559-562, 2008 | 321 | 2008 |
| Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial JC Shim, JGK Shin, DL Kelly, DU Jung, YS Seo, KH Liu, JH Shon, ... American Journal of Psychiatry 164 (9), 1404-1410, 2007 | 292 | 2007 |
| Integration of genetic, clinical, and INR data to refine warfarin dosing P Lenzini, M Wadelius, S Kimmel, JL Anderson, AL Jorgensen, ... Clinical Pharmacology & Therapeutics 87 (5), 572-578, 2010 | 266 | 2010 |
| Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions ME Klein, MM Parvez, JG Shin Journal of pharmaceutical sciences 106 (9), 2368-2379, 2017 | 221 | 2017 |
| Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects JY Park, KA Kim, MH Kang, SL Kim, JG Shin Clinical Pharmacology & Therapeutics 75 (3), 157-162, 2004 | 211 | 2004 |
| Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6 JG Shin, N Soukhova, DA Flockhart Drug metabolism and disposition 27 (9), 1078-1084, 1999 | 208 | 1999 |
| CYP2D6 Genotype and Adjuvant Tamoxifen: Meta‐Analysis of Heterogeneous Study Populations MA Province, MP Goetz, H Brauch, DA Flockhart, JM Hebert, R Whaley, ... Clinical Pharmacology & Therapeutics 95 (2), 216-227, 2014 | 201 | 2014 |
| Frequency of cytochrome P450 2C9 mutant alleles in a Korean population YR Yoon, JH Shon, MK Kim, YC Lim, HR Lee, JY Park, IJ Cha, JG Shin British journal of clinical pharmacology 51 (3), 277-280, 2001 | 191 | 2001 |
| High‐throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry MJ Kim, H Kim, IJ Cha, JS Park, JH Shon, KH Liu, JG Shin Rapid Communications in Mass Spectrometry: An International Journal Devoted …, 2005 | 188 | 2005 |
| Development of the “Inje Cocktail” for High‐throughput Evaluation of Five Human Cytochrome P450 Isoforms in vivo JY Ryu, IS Song, YE Sunwoo, JH Shon, KH Liu, IJ Cha, JG Shin Clinical Pharmacology & Therapeutics 82 (5), 531-540, 2007 | 156 | 2007 |
| Inhibitory effects of fruit juices on CYP3A activity H Kim, YJ Yoon, JH Shon, IJ Cha, JG Shin, KH Liu Drug metabolism and disposition 34 (4), 521-523, 2006 | 153 | 2006 |
| Incidence of S‐mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics DR Sohn, M Kusaka, T Ishizaki, SG Shin, IJ Jang, JG Shin, K Chiba Clinical Pharmacology & Therapeutics 52 (2), 160-169, 1992 | 153 | 1992 |
| The effect of SLCO1B1* 15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1* 15 JW Deng, IS Song, HJ Shin, CW Yeo, DY Cho, JH Shon, JG Shin Pharmacogenetics and genomics 18 (5), 424-433, 2008 | 151 | 2008 |
| Protein-kinase-C-mediated β-catenin phosphorylation negatively regulates the Wnt/β-catenin pathway J Gwak, M Cho, SJ Gong, J Won, DE Kim, EY Kim, SS Lee, M Kim, TK Kim, ... Journal of cell science 119 (22), 4702-4709, 2006 | 130 | 2006 |
| Hexachlorophene inhibits Wnt/β-catenin pathway by promoting Siah-mediated β-catenin degradation S Park, J Gwak, M Cho, T Song, J Won, DE Kim, JG Shin, S Oh Molecular pharmacology 70 (3), 960-966, 2006 | 129 | 2006 |
| Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin JE Park, KB Kim, SK Bae, BS Moon, KH Liu, JG Shin Xenobiotica 38 (9), 1240-1251, 2008 | 128 | 2008 |
